enGene (NASDAQ:ENGN) Insider William Grossman Buys 5,102 Shares of Stock

enGene Holdings Inc. (NASDAQ:ENGN) insider William Grossman purchased 5,102 shares of the firm’s stock in a transaction on Tuesday, September 22nd. The stock was bought at an average cost of $1.97 per share, with a total value of $10,050.94. Following the acquisition, the insider owned 5,102 shares of the company’s stock, valued at approximately $10,050.94. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

enGene Price Performance

Shares of ENGN opened at $1.92 on Friday. The firm has a market capitalization of $128.68 million, a PE ratio of -1.70 and a beta of -0.28. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.21 and a quick ratio of 10.21. enGene Holdings Inc. has a 1-year low of $1.40 and a 1-year high of $12.25. The company’s fifty day moving average price is $1.83 and its 200-day moving average price is $3.39.

enGene (NASDAQ:ENGN) last issued its earnings results on Tuesday, September 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). On average, equities research analysts predict that enGene Holdings Inc. will post -1.81 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ENGN shares. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of enGene in a report on Tuesday, September 8th. Citigroup reiterated a “market perform” rating on shares of enGene in a report on Wednesday, September 9th. Wall Street Zen raised shares of enGene from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Morgan Stanley cut shares of enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price objective for the company. in a research note on Thursday, June 18th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of enGene in a report on Wednesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $11.05.

Institutional Investors Weigh In On enGene

Hedge funds have recently bought and sold shares of the stock. Monashee Investment Management LLC boosted its stake in shares of enGene by 8.5% during the 1st quarter. Monashee Investment Management LLC now owns 320,000 shares of the company’s stock worth $2,179,000 after acquiring an additional 25,000 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of enGene during the 1st quarter valued at about $251,000. Eversept Partners LP increased its stake in shares of enGene by 12.0% in the 1st quarter. Eversept Partners LP now owns 510,543 shares of the company’s stock valued at $3,477,000 after purchasing an additional 54,708 shares in the last quarter. Sei Investments Co. purchased a new position in shares of enGene in the 1st quarter valued at about $409,000. Finally, Renaissance Technologies LLC raised its holdings in enGene by 651.1% in the 1st quarter. Renaissance Technologies LLC now owns 156,100 shares of the company’s stock worth $1,063,000 after purchasing an additional 135,318 shares during the period. Hedge funds and other institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.